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Background: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic
factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of
current alcohol or drug abuse, comorbid anxiety, or personality disorders.
Methods: Fifty-one patients with MDD (M/F, 19:32; age, 38 ± 19 years) and 51 healthy controls (M/F, 22:29; age,
34 ± 17 years) were studied using DSM-IV-TR: physically healthy and free of current alcohol or drug abuse, comorbid
anxiety, or personality disorders. Serum levels of proBDNF and MDNF were measured by sandwich enzyme-linked
immunosorbent assay (ELISA).
Results: Serum mature BDNF levels in the MDD patients were significantly lower than those in the healthy controls
(t = 3.046, p = 0.0018). On the other hand, no difference was found in serum proBDNF between the MDD patients
and the healthy controls (t = −0.979, p = 0.833). A trend of negative correlation was found between baseline serum
BDNF and baseline scores of the 17 items of the Hamilton Rating Scale for Depression (HAMD17) (r = −0.183, p =
0.071). No correlation was however found between HAMD17 scores and proBDNF at baseline (r = 0.092, p = 0.421).
Furthermore, no correlation was observed between baseline HAMD17 scores and baseline proBDNF/BDNF (r = −0.130,
p = 0.190). No changes were observed in serum levels of proBDNF and BDNF during the treatment periods.
Conclusions: These results suggest that there is no association between serum proBDNF/BDNF and fluvoxamine
response in MDD patients at least within 4 weeks of the treatment.
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Major depressive disorder (MDD) is a common and major
psychiatric disorder that affects as many as about 20% of
individuals within their lifetime [1-3]. A wide variety of
pharmaceuticals are available for treating depression, in-
cluding tricyclic antidepressants, monoamine oxidase
inhibitors, and selective serotonin reuptake inhibitors
(SSRIs). Fluvoxamine is an SSRI that is widely used for
treatment of depression and other psychiatric disorders
and has been suggested to have early effects when used as* Correspondence: yoshi621@med.uoeh-u.ac.jp
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article, unless otherwise stated.an antidepressant drug [4,5]. In addition, the results of a
meta-analysis have shown that significant improvements
in Hamilton Rating Scale for Depression (HAMD) scores
achieved in the first few weeks were maintained after
6 weeks of treatment [6]. Results of a recent meta-analysis
also suggest that treatment with fluvoxamine leads to
symptomatic improvements in patients with MDD by the
end of the first week of use [6].
Mature brain-derived neurotrophic factor (BDNF) is ini-
tially synthesized as a precursor protein. ProBDNF is con-
verted to BDNF by extracellular proteases such as matrix
metalloproteinase-9 (MMP-9). BDNF is biologically active.
In contrast, proBDNF, which localizes intracellularly, serves
as an inactive precursor. In short, new evidence shows thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographics of participants
Values
Age (years) 38 (19)
Female (%) 62
Daily dose at week 4 (max) (mg) 103 (38)
DUP (months) 2.1 (0.9)
HAMD17 (baseline) 19.3 (2.8)
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trophin receptor p75 (p75NTR) and tropomyosin-related
kinase B (TrkB) receptors, respectively, and that both
proBDNF and mature BDNF play important roles in several
physiological functions for neurons, which might be related
to the pathology of psychiatric disorders such as mood dis-
orders and schizophrenia [7-9]. Sen et al. [10] first per-
formed a meta-analysis and demonstrated that serum
BDNF levels are abnormally low in patients suffering from
major depressive disorder and that the BDNF levels are
elevated following a course of antidepressant treatment.
Although the relationship of our findings to the patho-
physiology of depression and the mechanism of drug
action remains to be determined, the measure may have
potential use as a biomarker for psychiatric disorders or as
a predictor of antidepressant efficacy [10,11]. Recently,
Yoshida et al. [12] reported that it was initially thought
that only secreted mature BDNF was biologically active
and that proBDNF, which localizes intracellularly, served
as an inactive precursor. However, new evidence shows
that proBDNF and BDNF elicit opposing effects via the
p75NTR and TrkB receptors, respectively, and that both
proBDNF and BDNF play important roles in several
physiological functions [8,12]. In recent decades, the role
of BDNF in first-episode major depressive disorder MDD
patients has received intensive attention. However, the re-






















Figure 1 The HAMD17 scores and serum proBDNF. Red line shows theclearly elucidated. We hypothesized that (1) serum levels
of BDNF, proBDNF, and proBDNF/BDNF are different be-
tween MDD patients and healthy controls, (2) fluvox-
amine decreases serum proBDNF level and proBDNF/
BDNF ratio and increases serum BDNF level, and (3) the
plasma level of fluvoxamine is related to serum levels of
BDNF and the HAMD17 scores.
This study aimed to determine whether serum levels
of proBDNF/BDNF were different between MDD patients
and the healthy controls. We also examined serum levels of
proBDNF/BDNF between the responders and the nonre-
sponders to fluvoxamine in patients with first-episode
MDD. In addition, we also investigated longitudinal changes
in proBDNF and BDNF in MDD patients treated with flu-
voxamine before and after the treatment.
To the best of our knowledge, this is the first study in-




Fifty-one drug-naïve and first-episode patients with MDD
were studied. In the MDD group, 19 were males and 32
were females, ranging in age from 29 to 71 (mean ± stand-
ard deviation (SD), 38 ± 19) years. In 51 cases of the
healthy control (HC) group, 22 males and 29 females, ran-
ging in age from 24 to 68 (mean ± SD, 35 ± 16) years, were
enrolled in the present study. Prior to the commencement
of the study, all subjects provided written informed con-
sent, after receiving a full explanation of the study as well
as any potential risks and benefits of study participation.
The study was approved by the Ethics Committee of the
University of Occupational and Environmental Health and
performed in accordance with the Declaration of Helsinki
II. The demographics of the participants are shown in
























Figure 2 Serum proBDNF change during treatment with fluvoxamine. Red line shows the mean of value.
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Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR): physically
healthy and free of current alcohol or drug abuse, comor-
bid anxiety, or personality disorders. We defined the re-
sponders as those whose scores of the 17 items of the
Hamilton Rating Scale for Depression (HAMD17) de-
creased 50% or more. All patients consented to participate
after having been informed of the study's purpose. Benzo-
diazepines were the only hypnotics permitted, and their
dosages were kept constant throughout the study period.
The dosages of fluvoxamine varied among patients and
were not fixed for ethical reasons.
Assessment of clinical variables
Depression was assessed using the 17 items of the Struc-
tured Interview Guide for the Hamilton Depression Rating














Figure 3 Serum proBDNF in the responders' and the
nonresponders' treatment with fluvoxamine.Serum proBDNF and BDNF assay
Blood was drawn at 9:00 a.m. Serum levels of BDNF and
proBDNF were measured in duplicate using the human
proBDNF enzyme-linked immunosorbent assay (ELISA)
kit SK00572-06 (Adipo Bioscience, Santa Clara, CA,
USA) and the human matureBDNF ELISA kit SK00572-01
(Adipo Bioscience, Santa Clara, CA, USA). All experiments
were performed in duplicate. Protocols were performed ac-
cording to the manufacturer's instructions. In short, 96-well
microplates were coated with anti-BDNF monoclonal anti-
body and incubated at 4°C for 18 h. The plates were incu-
bated in a blocking buffer for 1 h at room temperature. The
samples were diluted 100-fold with an assay buffer, and
BDNF standards were kept at room temperature with hori-
zontal shaking for 2 h and then washed with the appropri-
ate washing buffer. The plates were incubated with
antihuman BDNF polyclonal antibody at room temperature
for 2 h and washed with the washing buffer. Then, they
were incubated with anti-IgY antibody conjugated to
horseradish peroxidase for 1 h at room temperature and
incubated again in peroxidase substrate and tetramethyl-
benzidine solution to induce a color reaction. The reaction
was stopped with 1 mol/L hydrochloric acid. The absorb-
ance at 450 nm was measured with an Emax automated
microplate reader (Molecular Devices, Chuo-ku, Japan).
Measurements were performed in duplicate.
Plasma fluvoxamine assay
The plasma fluvoxamine level was measured using high-
performance liquid chromatography according to the
method we previously described [13]. In brief, 1 mL of
plasma alkalized with 500 μL of 2 M sodium hydrogen
carbonate was extracted by hexane (10 mL) after the
addition of the internal standard (clomipramine). Shaken
horizontally for 20 min and then centrifuged at 2,000 g for
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Figure 4 The HAMD17 scores and serum BDNF. Red line shows
the mean of value.
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a 50-μL aliquot of the final preparation was subjected to
HPLC. All experiments were performed in duplicate.Statistical analyses
Student's t test was used to compare two groups (serum
levels of proBDNF and BDNF; healthy control vs. MDD).
Serum levels of proBDNF and BDNF and plasma fluvox-
amine concentrations were measured, and correlations
with clinical variables were performed using Peason's cor-
relation. One-way ANOVA was used regarding the time
course of proBDNF and BDNF. Power analysis was per-
formed in BDNF (0 week) × HAMD17 (0 week) and
BDNF (healthy control, 0 week) × BDNF (MDD, 0 week).
A significant value of p < 0.05 was judged as statistically
significant. All analyses were carried out using SPSS ver-





















Figure 5 Serum BDNF change during treatment with fluvoxamine.Results
The demographics of the participants are shown in Table 1.
Twenty-five of 51 (49%) MDD patients responded to flu-
voxamine at least within 4 weeks. Nine of 51 (18%) MDD
patients had remission. Serum BDNF of all subjects could
be measured. Serum proBDNF of 32 of 51 HC (63%) and
25 of 51 MDD patients (49%) could be assayed. Serum
BDNF levels in MDD were significantly lower than those in
HC (t = 3.046, p = 0.0018, 1-β = 82.3%) (Figure 1). On the
other hand, no difference was found in serum proBDNF
between the MDD patients and the HC (t = −0.979, p =
0.833) (Figure 2). Twenty-four of 51 MDD patients (47%)
responded to fluvoxamine treatment at least within 4 weeks.
No difference was found in baseline proBDNF between
responders and nonresponders (t = 1.837, p = 0.073). No
difference was also found in baseline BDNF between re-
sponders and nonresponders (t = 1.19, p = 0.23). A trend
for negative correlation was found between baseline serum
BDNF and baseline HAMD17 scores (r = −0.183, p = 0.071)
(Figure 3). No correlation was however found between the
HAMD17 scores and proBDNF at baseline (r = 0.092, p =
0.421) (Figure 4). No difference was found between serum
levels of proBDNF (r = 0.090, p = 0.336) (Figure 5) and
BDNF (r = −0.084, p = 0.730) (Figure 6) at week 0 in MDD
patients. No changes were observed in serum levels of
proBDNF at baseline, 2 weeks, and 4 weeks after adminis-
trating fluvoxamine (F = 2.580, p = 0.080) (Figure 7). No
changes were also observed in serum levels of BDNF
at baseline, 2 weeks, and 4 weeks after administrating
fluvoxamine (F = 0.579, p = 0.561) (Figure 8). Further-
more, no correlation was observed between baseline
HAMD17 scores and baseline proBDNF/BDNF in MDD
patients (r = −0.130, p = 0.190) (Figure 9). No correl-
ation was also found between plasma fluvoxamine levels
at week 4 and the changes in HAMD17 scores (r =






















Figure 6 Serum BDNF in the responders' and the nonresponders'
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Figure 7 Serum BDNF change during treatment with
























Figure 9 The proBDNF/BDNF ratio and plasma fluvoxamine
concentration.
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changes in serum BDNF levels (from 0 to 4 weeks) (r =
0.117, p = 0.691) (Figure 11).
Discussion
Recent meta-analyses demonstrated that mature BDNF
levels in serum in patients with MDD were decreased
compared to those in healthy controls. The result in the
present study regarding serum BDNF confirms the recent
meta-analyses [10,14,15]. Low serum mature BDNF levels
increased over the course of antidepressant treatment
[10,14,15]. We have previously reported that a significant
correlation was found between the HAMD17 score and
serum BDNF levels before pharmacotherapy [16]. In the
present study, we reconfirmed our previous finding. A
correlation was not however observed between serum
proBDNF levels and the HAMD17 scores before start-



















Figure 8 The proBDNF/BDNF ratio between the responders and
the nonresponders. Red line shows the mean of value.between serum levels of proBDNF/BDNF and HAMD17.
Taking these findings into account, the BDNF level, but
not proBDNF and proBDNF/BDNF, reflects the severity
of MDD. Moreover, no correlation was observed be-
tween serum fluvoxamine levels and serum levels of
proBDNF/BDNF. The result in the present study sug-
gests that the plasma fluvoxamine level was not inde-
pendent of proBDNF/BDNF in MDD patients after
fluvoxamine treatment. In addition, serum levels of
BDNF and proBDNF/BDNF did not change at least
4 weeks after fluvoxamine administration. However,
serum proBDNF increased during fluvoxamine treat-
ment but did not reach the statistically significant level.
Taking these findings into account, our hypothesis was
not confirmed. In other words, the influence of fluvox-
amine on serum levels of proBDNF, BDNF, and proBDNF/
BDNF is complicated. Another interpretation is that
4 weeks is not enough to alter the dynamics of proBDNF
and BDNF. Zhou et al. [17] reported that protein and
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Figure 10 The changes in the HAMD17 (0–4 weeks) and plasma
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Figure 11 The changes in the HAMD17 (0–4 weeks) and plasma concentration at week 4.
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The authors also demonstrated that the levels of BDNF
and proBDNF negatively and positively correlated with
major depression severity, respectively. These results sug-
gest that the balance between proBDNF and BDNF is dis-
turbed in MDD. Sodersten et al. [18] recently reported a very
interesting finding using two independent cohort studies
(Sahlgrenska cohort and Karolinska cohort). The au-
thors found that serum MDNF, proBDNF, the ratio of
BDNF/proBDNF, and interaction with MMP-9 were dif-
ferent between patients with bipolar disorders and
healthy controls. The function of proBDNF however re-
mains precisely elucidated.
Furthermore, there is little information about the role of
serum proBDNF. We know that a controversy exists about
the relationship between brain BDNF and peripheral
BDNF. A recent study reported that circulating BDNF
revealed a positive correlation with hippocampal BDNF,
which reinforces the relevance to identify a potentially
useful therapeutic biomarker [19].
No correlation was found between the changes in the
HAMD17 scores and plasma fluvoxamine levels, which
indicates that the effect of plasma fluvoxamine levels is
independent of an individual's depressive clinical effi-
cacy in fluvoxamine. In other words, the pharmacody-
namic factors of each patient might also be involved in
the effects of fluvoxamine. We should consider various
factors for predicting the treatment response, and it
could be more complicated in the fluvoxamine re-
sponse. The present study had several limitations: (i)
small samples, (ii) assaying serum proBDNF was tricky
and the detection rate of serum proBDNF was very low
using the ELISA kit, and (iii) we did not measure MMP-
9 levels. Thus, we are undergoing reconfirmation ofthese preliminary results using another ELISA kit or
Western blotting method.
Conclusions
We reconfirmed that serum levels of BDNF, but not
proBDNF or proBDNF/BDNF ratio, in MDD were lower
than those in healthy controls. Fluvoxamine however
did not change serum levels of BDNF, proBDNF, and
proBDNF/BDNF ratio at least within 4 weeks. Finally, no
correlations exist between plasma levels of fluvoxamine
and the changes in the HAMD17 scores or serum BDNF
levels. In short, there is no association between serum
levels of proBDNF, BDNF, or proBDNF/BDNF ratio and
fluvoxamine response in MDD patients at least within
4 weeks of treatment. Using a different antidepressant
medication on proBDNF/BDNF could be useful to deter-
mine the specificity of the effect of fluvoxamine.
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